USFDA11 Sept 2026, 11:38 am
Alembic Pharma's Vadodara Facility Clears USFDA Inspection
AI Summary
Alembic Pharmaceuticals Limited announced the successful completion of an unannounced onsite Bioequivalence inspection by the United States Food and Drug Administration (USFDA) at its facility in Vadodara, Gujarat. The inspection, conducted from August 31st to September 10th, 2026, concluded with no Form 483 observations, indicating compliance with regulatory standards. This successful inspection is crucial for the company's ability to export pharmaceutical products to the US market.
Key Highlights
- USFDA inspection at Vadodara Bioequivalence Facility completed successfully.
- No Form 483 observations were issued by the USFDA.
- Inspection conducted from August 31st to September 10th, 2026.
- Positive outcome reinforces regulatory compliance for US market access.
Price Impact
More from APLLTD